+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Malignant Mesothelioma - Pipeline Review, H2 2019

  • ID: 4866572
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 976 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Bayer AG
  • Delta-Fly Pharma Inc
  • Horizon Therapeutics PLC
  • Merck & Co Inc
  • Pharma Mar SA
  • MORE
Malignant Mesothelioma - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma - Pipeline Review, H2 2019, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.

Malignant mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Malignant Mesothelioma - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 9, 43, 33, 25, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 6 and 8 molecules, respectively.

Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Malignant Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Malignant Mesothelioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Mesothelioma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AbbVie Inc
  • Bayer AG
  • Delta-Fly Pharma Inc
  • Horizon Therapeutics PLC
  • Merck & Co Inc
  • Pharma Mar SA
  • MORE
Introduction
Malignant Mesothelioma - Overview
Malignant Mesothelioma - Therapeutics Development
Malignant Mesothelioma - Therapeutics Assessment
Malignant Mesothelioma - Companies Involved in Therapeutics Development
Malignant Mesothelioma - Drug Profiles
Malignant Mesothelioma - Dormant Projects
Malignant Mesothelioma - Discontinued Products
Malignant Mesothelioma - Product Development Milestones
Appendix

List of Tables
Table 1: Number of Products under Development for Malignant Mesothelioma, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 7: Number of Products under Development by Universities/Institutes, H2 2019
Table 8: Products under Development by Companies, H2 2019
Table 9: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 10: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 11: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 12: Products under Development by Companies, H2 2019 (Contd..4), H2 2019
Table 13: Products under Development by Companies, H2 2019 (Contd..5), H2 2019
Table 14: Products under Development by Companies, H2 2019 (Contd..6), H2 2019
Table 15: Products under Development by Universities/Institutes, H2 2019
Table 16: Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Table 17: Number of Products by Stage and Target, H2 2019
Table 18: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 19: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Table 20: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
Table 21: Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
Table 22: Number of Products by Stage and Mechanism of Action, H2 2019
Table 23: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 24: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Table 25: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
Table 26: Number of Products by Stage and Route of Administration, H2 2019
Table 27: Number of Products by Stage and Molecule Type, H2 2019
Table 28: Malignant Mesothelioma - Pipeline by AbbVie Inc, H2 2019
Table 29: Malignant Mesothelioma - Pipeline by ADC Therapeutics SA, H2 2019
Table 30: Malignant Mesothelioma - Pipeline by Agios Pharmaceuticals Inc, H2 2019
Table 31: Malignant Mesothelioma - Pipeline by Aldeyra Therapeutics Inc, H2 2019
Table 32: Malignant Mesothelioma - Pipeline by Almac Discovery Ltd, H2 2019
Table 33: Malignant Mesothelioma - Pipeline by Amphera BV, H2 2019
Table 34: Malignant Mesothelioma - Pipeline by AnGes Inc, H2 2019
Table 35: Malignant Mesothelioma - Pipeline by Apollomics Inc, H2 2019
Table 36: Malignant Mesothelioma - Pipeline by Applied Research using OMIC Sciences SL, H2 2019
Table 37: Malignant Mesothelioma - Pipeline by Argenx SE, H2 2019
Table 38: Malignant Mesothelioma - Pipeline by ArQule Inc, H2 2019
Table 39: Malignant Mesothelioma - Pipeline by Ascentage Pharma Group International, H2 2019
Table 40: Malignant Mesothelioma - Pipeline by AstraZeneca Plc, H2 2019
Table 41: Malignant Mesothelioma - Pipeline by Atara Biotherapeutics Inc, H2 2019
Table 42: Malignant Mesothelioma - Pipeline by Aurigene Discovery Technologies Ltd, H2 2019
Table 43: Malignant Mesothelioma - Pipeline by Bayer AG, H2 2019
Table 44: Malignant Mesothelioma - Pipeline by BerGenBio ASA, H2 2019
Table 45: Malignant Mesothelioma - Pipeline by Biocad, H2 2019
Table 46: Malignant Mesothelioma - Pipeline by Biogen Inc, H2 2019
Table 47: Malignant Mesothelioma - Pipeline by Bionomics Ltd, H2 2019
Table 48: Malignant Mesothelioma - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Table 49: Malignant Mesothelioma - Pipeline by Boston Biomedical Inc, H2 2019
Table 50: Malignant Mesothelioma - Pipeline by Bristol-Myers Squibb Co, H2 2019
Table 51: Malignant Mesothelioma - Pipeline by Calithera Biosciences Inc, H2 2019
Table 52: Malignant Mesothelioma - Pipeline by CanBas Co Ltd, H2 2019
Table 53: Malignant Mesothelioma - Pipeline by Canget BioTekpharma LLC, H2 2019
Table 54: Malignant Mesothelioma - Pipeline by Checkpoint Therapeutics Inc, H2 2019
Table 55: Malignant Mesothelioma - Pipeline by Chiome Bioscience Inc, H2 2019
Table 56: Malignant Mesothelioma - Pipeline by Clovis Oncology Inc, H2 2019
Table 57: Malignant Mesothelioma - Pipeline by CStone Pharmaceuticals Co Ltd, H2 2019
Table 58: Malignant Mesothelioma - Pipeline by Deciphera Pharmaceuticals Inc, H2 2019
Table 59: Malignant Mesothelioma - Pipeline by Delta-Fly Pharma Inc, H2 2019
Table 60: Malignant Mesothelioma - Pipeline by Eli Lilly and Co, H2 2019

List of Figures
Figure 1: Number of Products under Development for Malignant Mesothelioma, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AbbVie Inc
  • ADC Therapeutics SA
  • Agios Pharmaceuticals Inc
  • Aldeyra Therapeutics Inc
  • Almac Discovery Ltd
  • Amphera BV
  • AnGes Inc
  • Apollomics Inc
  • Applied Research using OMIC Sciences SL
  • Argenx SE
  • ArQule Inc
  • Ascentage Pharma Group International
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • Aurigene Discovery Technologies Ltd
  • Bayer AG
  • BerGenBio ASA
  • Biocad
  • Biogen Inc
  • Bionomics Ltd
  • Boehringer Ingelheim International GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Co
  • Calithera Biosciences Inc
  • CanBas Co Ltd
  • Canget BioTekpharma LLC
  • Checkpoint Therapeutics Inc
  • Chiome Bioscience Inc
  • Clovis Oncology Inc
  • CStone Pharmaceuticals Co Ltd
  • Deciphera Pharmaceuticals Inc
  • Delta-Fly Pharma Inc
  • Eli Lilly and Co
  • EnGeneIC Ltd
  • Epigene Therapeutics Inc
  • Epizyme Inc
  • F. Hoffmann-La Roche Ltd
  • FKD Therapies Oy
  • Flag Therapeutics Inc
  • Genelux Corp
  • GlaxoSmithKline Plc
  • H2Biologics Inc
  • Harpoon Therapeutics Inc
  • Hebei Senlang Biotechnology Inc Ltd
  • Horizon Therapeutics PLC
  • Hutchison MediPharma Ltd
  • IDAC Theranostics Inc
  • Incyte Corp
  • Infinity Pharmaceuticals Inc
  • Inhibrx Inc
  • Inventiva
  • Invion Ltd
  • Juno Therapeutics Inc
  • Karyopharm Therapeutics Inc
  • L.E.A.F. Pharmaceuticals LLC
  • Laboratoires Pierre Fabre SA
  • Leucid Bio Ltd
  • LipoSeuticals Inc
  • MacroGenics Inc
  • Marino Biotechnology Co Ltd
  • MELEMA Pharma GmbH
  • Merck & Co Inc
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • Minneamrita Therapeutics LLC
  • Molecular Partners AG
  • MolMed SpA
  • Morphotek Inc
  • MTG Biotherapeutics Inc
  • NeoTX Therapeutics Ltd
  • Novartis AG
  • Oasmia Pharmaceutical AB
  • Oncology Venture U.S. Inc
  • Ono Pharmaceutical Co Ltd
  • OSE Immunotherapeutics
  • Pharma Mar SA
  • PlumeStars Srl
  • Polaris Pharmaceuticals Inc
  • Seattle Genetics Inc
  • SELLAS Life Sciences Group Inc
  • Shanghai GeneChem Co Ltd
  • Targovax ASA
  • TCR2 Therapeutics Inc
  • TRACON Pharmaceuticals Inc
  • TREAT U SA
  • Ube Industries Ltd
  • VasGene Therapeutics Inc
  • Venus Remedies Ltd
  • Verastem Inc
  • Y's Therapeutics Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll